Breaking Down Biotech Innovations with Dr. Bob Langer
Today’s guest is MIT professor, chemical engineer, scientist, inventor, and investor Dr. Bob Langer. Dr. Langer has over 1,400 granted or pending patents and has been cited 374,000 times (and counting)! As a co-founder of Moderna, he has great insights into the potential of mRNA to treat diseases of various descriptions. Joining us to pick this extraordinary mind is clinically trained entrepreneur, Dr. Charlie Roberts. In this conversation, we discuss emerging biotechnologies, the potential of artificial intelligence (AI) in this space, as well as what might be attributed to the current downturn of the market. Dr. Langer lists potential time-to-market accelerators for new therapies and vaccines and shares his advice for those looking to make an impact from an academic and/or entrepreneurial standpoint. Tune in to hear more about the innovations Dr. Langer has been involved in over the years, and what we can look forward to in the future! Key Points From This Episode: Dr. Bob Langer highlights his favorite patent. Dr. Langer’s career achievements. Some factors impacting the current biotech market downturn. The correlation between magic and science. What mRNA is and why it’s an ideal candidate for treating disease. The personalized cancer vaccines Merck and Moderna are currently developing. Under what circumstances mRNA isn’t the solution. The emerging biotechnologies Dr. Langer is most excited about. The applications of organs on a chip. The potential of AI in the biotech space. Potential time-to-market accelerators for new therapies and vaccines. How to make an impact in the academic and entrepreneurial biotech spaces. The importance of understanding intellectual property. The team aspect of innovation. Dr. Langer’s tales of perseverance. Strategies for enforcing IPs. Dr. Langer’s delivery expertise. How he’s balanced his work and family life over the years. More FYI Podcasts: https://ark-invest.com/podcasts/ To learn more about ARK: https://ark-invest.com/ For more updates, follow us on: Twitter: https://arkinv.st/3corDiY LinkedIn: http://arkinv.st/1f7AiVX Facebook: http://arkinv.st/3r4EDOU Instagram: http://arkinv.st/39td8bO Disclosure: http://arkinv.st/39rzF94More FYI Podcasts: https://ark-invest.com/podcasts/

Venture Capital Perspectives: Early Stage Biotech Investing with Doug Cole, Flagship Ventures

Bettering Human Health Through Artificial Intelligence with Sean McClain and Joshua Meier of Absci

346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine

From Controversy To Cure - Inside the Cambridge Biotech Boom

This is not the AI we were promised | The Royal Society

Navigating a Triple COP year: What businesses need to know (Business for Nature webinar)

Editing Your DNA, with Nobel Prize Winner Dr. Jennifer Doudna

Best of 2022 – FYI Podcast Compilation

Biotech Story Time With Tal Zaks, M.D. (Part 1)

JUST RECORDED: Elon Musk Announces SPACEX Plans

The Future of AI with Manu Sharma

Scientist Stories: Robert Langer, Using Chemical and Biomedical Engineering to Advance Biomedicine

Yann LeCun Says LLMs Have 2 Years Left…

SpaceX: The IPO where the math doesn't matter | About That

Internet of Things (IoT) and Forensics with Oren Upton

Ted Oakley: Wall Street Is Running Investors Off A Cliff

Jensen Huang of Nvidia on the Future of A.I. | DealBook Summit 2023

BIOTECHNOLOGY in the Future & How AI is Revolutionizing Biology ft. Hannah Wastyk

President Trump’s $2 Billion Quantum Bet

